Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53-Reference-Cited by-同舟云学术

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53

Published:2019-02-18 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Tirrò Elena,Massimino Michele,Romano Chiara,Pennisi Maria Stella,Stella Stefania,Vitale Silvia Rita,Fidilio Annamaria,Manzella Livia,Parrinello Nunziatina Laura,Stagno Fabio,Palumbo Giuseppe Alberto,La Cava Piera,Romano Alessandra,Di Raimondo Francesco,Vigneri Paolo G.

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference63 articles.

1. Cancer statistics, 2015;Siegel,2015

2. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery;Jaffe,2008

3. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993;Rowe,2005

4. Modern therapy of acute lymphoblastic leukemia;Bassan,2011

5. Acute lymphoblastic leukemia: a comprehensive review and 2017 update;Terwilliger,2017

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL;Blood;2024-07-04

2. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL;Blood Advances;2024-06-14

3. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair;Oncology Reports;2024-05-21

4. Burkitt's Lymphoma;Comprehensive Hematology and Stem Cell Research;2024

5. Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy;Haematologica;2023-12-21